Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intra-Cellular Therapies (ITCI) reports stellar Q4 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q4 2022, driven by robust sales growth of CAPLYTA and a focus on expanding clinical programs.
While facing challenges in managing expenses and navigating market dynamics, the company is well-positioned to capitalize on opportunities in new indications and patient education initiatives.
ITCI's strategic investments in innovation and market expansion underscore its commitment to long-term growth and addressing mental health needs through novel treatment options.

Intra-Cellular Therapies reports robust Q1 performance and growth prospects

ITCI's strong Q1 performance driven by CAPLYTA and promising results from lumateperone studies position the company well for future growth.
Addressing unmet needs in MDD and bipolar depression, along with ongoing pipeline progress, showcases ITCI's commitment to innovation in neuropsychiatric treatments.
While facing challenges in market share data and increasing expenses, opportunities lie in expanding sales force, new indications for pipeline programs, and driving awareness for CAPLYTA.

Intra-Cellular Therapies (ITCI) reports strong Q2 performance and expands treatment portfolio

Intra-Cellular Therapies (ITCI) demonstrated robust performance in Q2, driven by strong revenue growth and promising developments in its product portfolio.
The company's financial strength, innovative pipeline, and focus on addressing unmet medical needs position it well for future growth and success.
While facing challenges in revenue guidance clarity and resource allocation, ITCI has opportunities to expand its market reach and improve patient outcomes.
By leveraging its strengths and addressing challenges effectively, Intra-Cellular Therapies (ITCI) can capitalize on opportunities to drive continued growth and innovation.

Intra-Cellular Therapies (ITCI) excels in Q3, eyes market expansion

Intra-Cellular Therapies (ITCI) showcased strong financial performance and growth prospects in Q3 2023, driven by CAPLYTA's success and pipeline advancements.
While the company faces challenges in sustaining growth and navigating regulatory complexities, opportunities in market expansion and innovation are key for future success.
ITCI's focus on expanding indications, clinical advancements, and financial strength position it well for continued growth and leadership in the pharmaceutical industry.

Intra-Cellular Therapies (ITCI) reports robust growth and strategic expansion

Intra-Cellular Therapies (ITCI) delivered a strong performance in 2023, with robust revenue growth and strategic plans for pipeline advancement and market expansion.
The company faces challenges in managing expenses, optimizing market penetration, and navigating competitive dynamics, but opportunities in sales growth and innovation are evident.
Overall, Intra-Cellular Therapies (ITCI) is well-positioned for continued success, with a focus on driving growth through product differentiation and market positioning.

Intra-Cellular Therapies (ITCI) reports strong Q1 earnings and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong Q1 2024 earnings driven by robust CAPLYTA sales and positive results in MDD studies, positioning the company for future growth.
With a solid financial position, a broad label strategy, and a focus on pipeline expansion, ITCI is well-equipped to capitalize on market opportunities and drive long-term success.
While facing near-term uncertainties and challenges, ITCI's strategic initiatives and ongoing studies present significant opportunities for expanding its market reach and revenue potential.
Overall, ITCI's commitment to developing innovative medicines and its market acceptance indicate a promising outlook for sustained growth and value creation.

Intra-Cellular Therapies (ITCI) reports robust Q3 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q3 2024, driven by CAPLYTA's sales growth and strategic investments in R&D.
The company's focus on innovation, with new program initiations and pipeline advancements, positions it well for future growth and market expansion.
While facing challenges in a competitive market and cost management, ITCI's solid financial position and promising pipeline offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to previous or another approved antipsychotic.

CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 9:10 am ET.

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference

The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And it's been trading in cyclical growth spurts of gives and takes. Investors are eyeing Caplyta sales to ascertain that the drug has strong sales prospects. Moreover, they want to see additional catalysts materialize.

Intra-Cellular Therapies: Another Growth Cycle Approaching

Alexion Pharma

These two biotech companies are safe bargains in today's volatile market.

2 Underrated Biotech Stocks to Buy Now

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 9:15am ET.

Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) remained unaffected after the company reported Q3 results.

Recap: Intra-Cellular Therapies Q3 Earnings

P ositive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.

Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update

CRISPR Therapeutics

Innovation might be worth the high risk up front investment.

Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, November 9, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2020.

Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Dr. Suresh Durgam to the position of Chief Medical Officer. Additionally, Dr. Andrew Satlin will step down as Chief Medical Officer, and will leave the Company effective October 28, 2020 to pursue a new opportunity. 

Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer

The potential label expansion of lumateperone in bipolar depression could be a major breakthrough.

Does This Pharma Company's Lead Asset Make it a Buy Today?

NEW YORK, Sept.  14, 2020  (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:00 am ET.

Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference

Shares of a New York City biotechnology company shot up nearly 73% Wednesday, sparked by news that a drug it's testing could hit sales of more than $1 billion, earning it blockbuster status.

Anti-Depressant OK Could Boost Intra-Cellular Drug into Blockbuster Territory

Lululemon Athletica

A nice bounce for the market was overdue.

Nasdaq Soars Nearly 300 Points as Intra-Cellular Breaks Through; a Lemon for Lululemon?

Intra-Cellular Therapies (ITCI) is in the news Wednesday after announcing positive results from a recent study that sent ITCU stock soaring.
The post Intra-Cellular Therapies News: Why ITCI Stock Is Skyrocketing 75% Today appeared first on InvestorPlace.

Intra-Cellular Therapies News: Why ITCI Stock Is Skyrocketing 75% Today

Intra-Cellular Therapies on Wednesday revealed positive final-phase test results for a treatment for certain Bipolar I and Bipolar II disorders, sending ITCI stock soaring more than 70%.
The post Positive Test Results For Bipolar Treatment Sends Intra-Cellular Stock Soaring appeared first on Investor's Business Daily.

Positive Test Results For Bipolar Treatment Sends Intra-Cellular Stock Soaring

Investors are reacting enthusiastically to the company's latest clinical results.

Why Intra-Cellular Therapies Stock Is Skyrocketing Today

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) was one of the biggest winners on Wednesday after the company announced positive results from its late-stage clinical trial in patients with bipolar disorder.

Intra-Cellular Therapies Finds Euphoria in Bipolar Study Results

Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) in late 2020 or early 2021.

Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression

Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2020 Results - Earnings Call Transcript

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Intra-Cellular Therapies Stock (ITCI)